Novartis (NYSE:NVS) was downgraded by Barclays from an “equal weight” rating to a “sell” rating in a note issued to investors on Friday, The Fly reports.

Several other equities research analysts also recently weighed in on NVS. Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating in a report on Wednesday, August 29th. Bank of America upgraded Novartis from an “underperform” rating to a “buy” rating and set a $74.71 price target for the company in a research note on Monday, September 10th. Citigroup upgraded Novartis from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 11th. Exane BNP Paribas upgraded Novartis from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 11th. Finally, ValuEngine upgraded Novartis from a “sell” rating to a “hold” rating in a research note on Wednesday, September 12th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Novartis presently has an average rating of “Hold” and a consensus price target of $85.91.

Shares of NVS stock traded down $1.97 during trading hours on Friday, hitting $87.08. The stock had a trading volume of 2,925,759 shares, compared to its average volume of 1,960,280. The company has a market capitalization of $209.68 billion, a P/E ratio of 18.10, a PEG ratio of 2.01 and a beta of 0.74. Novartis has a twelve month low of $72.30 and a twelve month high of $94.19. The company has a current ratio of 1.20, a quick ratio of 0.96 and a debt-to-equity ratio of 0.29.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Thursday, October 18th. The company reported $1.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.01. The business had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $12.88 billion. Novartis had a return on equity of 15.81% and a net margin of 25.98%. The company’s revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.29 earnings per share. Research analysts predict that Novartis will post 5.17 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Matthew Goff Investment Advisor LLC raised its position in Novartis by 2.5% in the third quarter. Matthew Goff Investment Advisor LLC now owns 39,957 shares of the company’s stock worth $3,443,000 after acquiring an additional 969 shares in the last quarter. Great Lakes Advisors LLC raised its position in Novartis by 4.4% in the third quarter. Great Lakes Advisors LLC now owns 17,586 shares of the company’s stock worth $1,515,000 after acquiring an additional 740 shares in the last quarter. Clearbridge Investments LLC raised its position in Novartis by 10.1% in the third quarter. Clearbridge Investments LLC now owns 782,377 shares of the company’s stock worth $67,410,000 after acquiring an additional 71,953 shares in the last quarter. Carnegie Capital Asset Management LLC raised its position in Novartis by 15.6% in the third quarter. Carnegie Capital Asset Management LLC now owns 14,972 shares of the company’s stock worth $1,314,000 after acquiring an additional 2,021 shares in the last quarter. Finally, Reynders McVeigh Capital Management LLC raised its position in Novartis by 0.4% in the third quarter. Reynders McVeigh Capital Management LLC now owns 297,345 shares of the company’s stock worth $25,619,000 after acquiring an additional 1,315 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Read More: How Buying a Call Option Works

The Fly

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.